PNU-100480

06/01/2014 - "The data set included 690 PK determinations and 345 WBA determinations from 50 tuberculosis patients enrolled in a phase 2a sutezolid trial. "
01/01/2014 - "Further studies of sutezolid in tuberculosis treatment are warranted. "
01/01/2014 - "This study of sutezolid is its first in tuberculosis patients. "
06/01/2014 - "tuberculosis by orally administered sutezolid is mainly due to the activity of the parent compound. "
08/15/2009 - "Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis."

06/01/2014 - "Moreover, the potency of PNU-100480 was significantly greater than that of linezolid, making it an attractive drug candidate in the development of new combination therapies for latent tuberculosis. "
06/01/2014 - "Here, we compared the activities of three oxazolidinones, linezolid, PNU-100480, and AZD5847, against latent tuberculosis using a simple model employing the streptomycin-starved Mycobacterium tuberculosis strain 18b. "

08/15/2009 - "Together with previous findings, these results confirm that PNU-100480, which is now in Phase I clinical testing, has sterilizing activity in the murine model and suggest that it may be capable of shortening treatment duration for drug-susceptible as well as drug-resistant tuberculosis in humans."
04/01/2009 - "These results suggest that PNU-100480 may have the potential to significantly shorten the duration of therapy for drug-susceptible as well as multidrug-resistant tuberculosis."
04/01/2015 - "After decades of quiescence in the development of antituberculosis medications, bedaquiline and delamanid have been conditionally approved for the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II clinical trials. "
01/01/2017 - "This paper is also focused on some interesting molecules in treating multidrug-resistant tuberculosis which are currently tested in clinical studies: delamanid (dihydro-nitroimidazooxazole derivative, phase III), AZD5847 (oxazolidinone derivative, phase II), pretomanid (nitroimidazole derivative, phase III), sutezolid (oxazolidinone derivative, phase II) and SQ109 (ethambutol analogue, phase II) and some prospective molecules at the level of preclinical studies e.g., CPZEN-45, SQ609 and SQ641."

05/01/1999 - "A dose-response study was performed with PNU-100480 and linezolid (both at 25, 50, and 100 mg/kg of body weight). "
04/01/2009 - "For example, the addition of PNU-100480 (100 mg/kg of body weight/day) to the standard daily regimen of rifampin (rifampicin), isoniazid, and pyrazinamide resulted in an additional 2.0-log(10)-unit reduction in lung CFU counts during the first 2 months of treatment. "

01/01/2018 - "We found that miltefosine, azithromycin, clarithromycin, josamycin, linezolid, sutezolid, retapamulin, tiamulin, and valnemulin had inhibitory and cidal activity against the pathogens at concentrations ranging from 0.25 to 64 μg/ml. Our results suggest that these antimicrobials are promising candidates for future studies on pythiosis in animals and humans."